M Lin1, M Todaro2, J Chan3, L Churilov4, W S Zhu1, S Ramdave3, P J Mitchell5, R J Dowling5, P Kwan6, B Yan7. 1. From the Melbourne Brain Centre (M.L., W.S.Z., B.Y.). 2. Neurology (M.T., P.K., B.Y.), The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia Department of Medicine (M.T., J.C., S.R., P.K.), University of Melbourne, Melbourne, Victoria, Australia. 3. Department of Medicine (M.T., J.C., S.R., P.K.), University of Melbourne, Melbourne, Victoria, Australia. 4. Florey Institute of Neurosciences and Mental Health (L.C.), Melbourne Brain Centre, Heidelberg, Victoria, Australia. 5. Departments of Radiology (P.J.M., R.J.D., B.Y.). 6. Neurology (M.T., P.K., B.Y.), The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia Department of Medicine (M.T., J.C., S.R., P.K.), University of Melbourne, Melbourne, Victoria, Australia kwanp@unimelb.edu.au bernard.yan@mh.org.au. 7. From the Melbourne Brain Centre (M.L., W.S.Z., B.Y.) Departments of Radiology (P.J.M., R.J.D., B.Y.) Neurology (M.T., P.K., B.Y.), The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia kwanp@unimelb.edu.au bernard.yan@mh.org.au.
Abstract
BACKGROUND AND PURPOSE: Differing responses to clopidogrel following endovascular treatment of cerebrovascular diseases may increase the risk of vascular complications. CYP2C19 gene polymorphisms influence clopidogrel activity. We aimed to study the clinical impact of CYP2C19 gene polymorphisms in patients undergoing endovascular treatment. MATERIALS AND METHODS: This was a prospective, longitudinal, observational study. Information on demographics and cerebrovascular status was collected as baseline. Clopidogrel response was tested by the VerifyNow P2Y12 assay. CYP2C19 genotyping was undertaken by polymerase chain reaction-restriction fragment length polymorphism. Three-month follow-up data included vascular complications, mortality, and modified Rankin Scale score. Associations were investigated among CYP2C19 genotypes, clopidogrel responsiveness, and clinical outcomes. RESULTS: One hundred and eight participants were included. Median age was 56 years (interquartile range, 48.8-65.0 years), and 35 (32.4%) were male. Forty-four participants were classified into group 1 (homozygous CYP2C19*1/*1); 31, into group 2 (25 with CYP2C19*1/*2, two with CYP2C19*1/*3, three with CYP2C19*3/*3, one with CYP2C19*2/*3); 28, into group 3 (24 with CYP2C19*1/*17, four with CYP2C19*17/*17); and 5, into group 4 (CYP2C19*2/*17). A significantly higher proportion of participants in group 3 experienced ischemic events (9 of 28, 32.1%) compared with group 1 (5 of 44, 11.4%; P = .04; odds ratio, 3.7; 95% confidence interval, 1.1-12.6). There was no significant difference in clopidogrel response among the 4 genotype groups. CONCLUSIONS: Individuals with CYP2C19*17 may have increased risk of ischemic events following endovascular treatment, independent of clopidogrel responsiveness. Larger studies are required to confirm the influence of CYP2C19*17 on clinical outcomes and to understand the mechanisms for increased ischemic events.
BACKGROUND AND PURPOSE: Differing responses to clopidogrel following endovascular treatment of cerebrovascular diseases may increase the risk of vascular complications. CYP2C19 gene polymorphisms influence clopidogrel activity. We aimed to study the clinical impact of CYP2C19 gene polymorphisms in patients undergoing endovascular treatment. MATERIALS AND METHODS: This was a prospective, longitudinal, observational study. Information on demographics and cerebrovascular status was collected as baseline. Clopidogrel response was tested by the VerifyNow P2Y12 assay. CYP2C19 genotyping was undertaken by polymerase chain reaction-restriction fragment length polymorphism. Three-month follow-up data included vascular complications, mortality, and modified Rankin Scale score. Associations were investigated among CYP2C19 genotypes, clopidogrel responsiveness, and clinical outcomes. RESULTS: One hundred and eight participants were included. Median age was 56 years (interquartile range, 48.8-65.0 years), and 35 (32.4%) were male. Forty-four participants were classified into group 1 (homozygous CYP2C19*1/*1); 31, into group 2 (25 with CYP2C19*1/*2, two with CYP2C19*1/*3, three with CYP2C19*3/*3, one with CYP2C19*2/*3); 28, into group 3 (24 with CYP2C19*1/*17, four with CYP2C19*17/*17); and 5, into group 4 (CYP2C19*2/*17). A significantly higher proportion of participants in group 3 experienced ischemic events (9 of 28, 32.1%) compared with group 1 (5 of 44, 11.4%; P = .04; odds ratio, 3.7; 95% confidence interval, 1.1-12.6). There was no significant difference in clopidogrel response among the 4 genotype groups. CONCLUSIONS: Individuals with CYP2C19*17 may have increased risk of ischemic events following endovascular treatment, independent of clopidogrel responsiveness. Larger studies are required to confirm the influence of CYP2C19*17 on clinical outcomes and to understand the mechanisms for increased ischemic events.
Authors: Ankie M Harmsze; Jochem W van Werkum; Jurriën M Ten Berg; Bastiaan Zwart; Heleen J Bouman; Nicoline J Breet; Arnoud W J van 't Hof; Hendrik J T Ruven; Christian M Hackeng; Olaf H Klungel; Anthonius de Boer; Vera H M Deneer Journal: Eur Heart J Date: 2010-09-10 Impact factor: 29.983
Authors: Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati Journal: Circulation Date: 2010-01-18 Impact factor: 29.690
Authors: Maria Cohen; Ashley J Lamparello; Lukas Schimunek; Fayten El-Dehaibi; Rami A Namas; Yan Xu; A Murat Kaynar; Timothy R Billiar; Yoram Vodovotz Journal: Shock Date: 2020-03 Impact factor: 3.533
Authors: Axel Rosengart; Malie K Collins; Philipp Hendrix; Ryley Uber; Melissa Sartori; Abhi Jain; Jennifer Mao; Oded Goren; Clemens M Schirmer; Christoph J Griessenauer Journal: Interv Neuroradiol Date: 2021-02-04 Impact factor: 1.764
Authors: Pious D Patel; Xinnan Niu; Chevis N Shannon; Joshua C Denny; Josh F Peterson; Matthew R Fusco; Rohan V Chitale Journal: Transl Stroke Res Date: 2021-02-21 Impact factor: 6.829